AU2003249000B2 - Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer - Google Patents

Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer Download PDF

Info

Publication number
AU2003249000B2
AU2003249000B2 AU2003249000A AU2003249000A AU2003249000B2 AU 2003249000 B2 AU2003249000 B2 AU 2003249000B2 AU 2003249000 A AU2003249000 A AU 2003249000A AU 2003249000 A AU2003249000 A AU 2003249000A AU 2003249000 B2 AU2003249000 B2 AU 2003249000B2
Authority
AU
Australia
Prior art keywords
treatment
cancer
tumour
ionising radiation
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003249000A
Other languages
English (en)
Other versions
AU2003249000A1 (en
Inventor
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218525A external-priority patent/GB0218525D0/en
Priority claimed from GB0307560A external-priority patent/GB0307560D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003249000A1 publication Critical patent/AU2003249000A1/en
Application granted granted Critical
Publication of AU2003249000B2 publication Critical patent/AU2003249000B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003249000A 2002-08-09 2003-08-05 Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer Ceased AU2003249000B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0218525.4 2002-08-09
GB0218525A GB0218525D0 (en) 2002-08-09 2002-08-09 Combination therapy
GB0307560.3 2003-04-02
GB0307560A GB0307560D0 (en) 2003-04-02 2003-04-02 Combination therapy
PCT/GB2003/003388 WO2004014383A1 (en) 2002-08-09 2003-08-05 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2003249000A1 AU2003249000A1 (en) 2004-02-25
AU2003249000B2 true AU2003249000B2 (en) 2007-04-05

Family

ID=31716921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003249000A Ceased AU2003249000B2 (en) 2002-08-09 2003-08-05 Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer

Country Status (13)

Country Link
US (1) US20050222183A1 (enExample)
EP (1) EP1534287A1 (enExample)
JP (1) JP2006502132A (enExample)
KR (1) KR20050056190A (enExample)
CN (1) CN1313094C (enExample)
AU (1) AU2003249000B2 (enExample)
BR (1) BR0313116A (enExample)
CA (1) CA2495487A1 (enExample)
IL (1) IL166522A0 (enExample)
MX (1) MXPA05001458A (enExample)
NO (1) NO20050450L (enExample)
NZ (1) NZ537753A (enExample)
WO (1) WO2004014383A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676845B1 (en) 1999-11-05 2008-06-11 AstraZeneca AB New quinazoline derivatives
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1274692B1 (en) * 2000-04-07 2006-08-02 AstraZeneca AB Quinazoline compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
NZ534171A (en) * 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
BRPI0412426A (pt) * 2003-07-10 2006-09-05 Astrazeneca Ab uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente
BRPI0516052A (pt) * 2004-09-27 2008-08-19 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
EP1971338B8 (en) * 2005-12-22 2011-09-21 AstraZeneca AB Combination of zd6474 and pemetrexed
JP4945133B2 (ja) * 2006-01-19 2012-06-06 富士フイルムＲｉファーマ株式会社 ４−フェノキシキナゾリン誘導体放射性化合物
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
CN106317022A (zh) * 2015-06-25 2017-01-11 中美华世通生物医药科技（武汉）有限公司 化合物的制备方法和用途
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors

Also Published As

Publication number Publication date
CN1674905A (zh) 2005-09-28
NZ537753A (en) 2008-04-30
MXPA05001458A (es) 2005-06-06
NO20050450L (no) 2005-05-02
CA2495487A1 (en) 2004-02-19
JP2006502132A (ja) 2006-01-19
IL166522A0 (en) 2006-01-15
AU2003249000A1 (en) 2004-02-25
EP1534287A1 (en) 2005-06-01
CN1313094C (zh) 2007-05-02
KR20050056190A (ko) 2005-06-14
BR0313116A (pt) 2005-07-05
US20050222183A1 (en) 2005-10-06
WO2004014383A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
AU2003249000B2 (en) Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
CA2464758C (en) Combination therapy comprising zd6474 and a taxane
US20100130520A1 (en) Combination therapy
AU2002337382A1 (en) Combination therapy comprising ZD6474 and a taxane
KR20060033785A (ko) Ａｚｄ2171 및 ｚｄ1839를 포함하는 암 병행 요법
KR20060034287A (ko) 병용 요법
ES2364030T3 (es) Terapia de combinación de zd6474 con 5-fu y/o cpt-11.
HK1084032B (en) Combination therapy of zd6474 with 5-fu and/or cpt-11
HK1068546B (en) Combination therapy comprising zd6474 and a taxane

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired